In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Perkin-Elmer/PerSeptive Biosystems

This article was originally published in The Gray Sheet

Executive Summary

Perkin-Elmer/PerSeptive Biosystems: Hart-Scott-Rodino antitrust review of Perkin-Elmer's proposed $360 mil. acquisition of PerSeptive is extended as a result of a Department of Justice request for additional information related to the transaction. A definitive agreement for the deal was announced Aug. 25 ("The Gray Sheet" Sept. 1, p. 6). Both firms offer mass spectrometry products that enable lab technicians to analyze and sequence peptide and protein biomolecules; the firms maintain that their respective technologies are used in different phases of the drug discovery process. In addition to regulatory approval, the deal is contingent on a vote by PerSeptive shareholders, a meeting of which is slated for Dec. 4...

You may also be interested in...

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts